Short answer
Viatris (VTRS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3.7B (down 0.3% year over year) with net income of −$325M.
Q3 2026 key financials · XBRL
- Revenue
- $3.7B
- −0.3% YoY · −0.3% QoQ
- Net income
- −$325M
- −153.7% YoY · −173.8% QoQ
- Operating margin
- 7.0%
- Gross margin
- 38.5%
- EPS (diluted)
- −$0.28
- −133.3% YoY · −180.0% QoQ
Source: XBRL data from the Viatris (VTRS) Q3 2026 10-Q on SEC EDGAR. USD.
Viatris Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $3.75B vs $3.76B, down $10.4M YoY, essentially flat
- Gross margin 38% vs 36%; adjusted gross margin approximately 58% vs 56%
- Best segment Greater China: $702.6M, up 14%; worst Emerging Markets: $529.1M, down 7%
- Operating cash flow $1.67B through September, up $169.4M; repurchases $150.0M in Q3
- Nashik disruption: approximately $100M Q4 revenue impact; production expected to resume Q1 2027
Risk Factors
- New acquisition risk: Pacira transaction may fail or face delays due to tender, regulatory, legal and closing conditions
- Most material update: Pacira integration may underperform, limiting anticipated benefits, synergies and operating efficiencies
- Regulatory risk: Hart-Scott-Rodino waiting-period expiration required before Pacira offer completion
- Operational risk: Viatris may fail to retain Pacira talent supporting commercial, market access, medical affairs and R&D capabilities
- Financial risk: Transaction setbacks could affect cash flows, dividends, share repurchases and stock price
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Viatris quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.